The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

XDS

Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463

Refinement of Macromolecular Structures by the Maximum-Likelihood Method

Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796

MOLREP : an Automated Program for Molecular Replacement

Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,756

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity

Soderquist, R. S., Crawford, L. A., Liu, E., Lu, M., Agarwal, A., Anderson, G. R., Lin, K., Winter, P. S., Çakır, M., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-05815-z · Cited by 122

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

Barlaam, B. C., Casella, R., Cidado, J. R., Cook, C., Savi, C. D., Dishington, A. P., Donald, C. S., Drew, L., Ferguson, A. D., Ferguson, D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01754 · Cited by 121

Revealing the Impact of Structural Variants in Multiple Myeloma

Rustad, E. H., Yellapantula, V. D., Głodzik, D., Maclachlan, K. H., Diamond, B. T., Boyle, E. M., Ashby, C., Blaney, P., Gundem, G., Hultcrantz, M. L., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0132 · Cited by 122

Stressed to death: Mitochondrial stress responses connect respiration and apoptosis in cancer

Winter, J. M., Yadav, T., & Rutter, J. P. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.07.012 · Cited by 121

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Casara, P., Davidson, J. E. P., Clapéron, A., Toumelin-Braizat, G. L., Vogler, M., Bruno, A., Chanrion, M., Lysiak-Auvity, G., Diguarher, T. L., Starck, J.-B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24744 · Cited by 119

Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy

Bernardini, J. P., Brouwer, J. M., Tan, I. K. L., Sandow, J. J., Huang, S., Stafford, C. A., Bankovacki, A., Riffkin, C. D., Wardak, A. Z., Czabotar, P. E., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201899916 · Cited by 126

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Szlavik, Z., Csékei, M., Paczal, A., Szabo, Z. B., Sipos, S., Radics, G., Proszenyák, Á., Bálint, B., Murray, J. B., Davidson, J. E. P., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01234 · Cited by 117

Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933-946.

Jayappa, K. D., Portell, C. A., Gordon, V. L., Capaldo, B. J., Bekiranov, S., Axelrod, M. J., Brett, L. K., Wulfkuhle, J. D., Gallagher, R. I., Petricoin, E. F., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016004176 · Cited by 120

Viewing BCL2 and cell death control from an evolutionary perspective

Strasser, A., & Vaux, D. L. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.145 · Cited by 116

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Haselager, M. V., Kielbassa-Elkadi, K., ter Burg, J., Bax, D. J. C., Fernandes, S. M., Borst, J. G., Tam, C. S. L., Forconi, F., Chiodin, G., Brown, J. R., et al. (2020) · Blood · doi:10.1182/blood.2019004326 · Cited by 114

Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma

Gupta, V. A., Matulis, S. M., Conage-Pough, J. E., Nooka, A. K., Kaufman, J. L., Lonial, S., & Boise, L. H. (2017) · Blood · doi:10.1182/blood-2016-10-745059 · Cited by 113

A non-death function of the mitochondrial apoptosis apparatus in immunity

Brokatzky, D., Dörflinger, B., Haimovici, A., Weber, A., Kirschnek, S., Vier, J., Metz, A., Henschel, J., Steinfeldt, T., Gentle, I. E., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100907 · Cited by 112

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Moujalled, D. M., Brown, F. C., Chua, C. C., Dengler, M. A., Pomilio, G., Anstee, N. S., Litalien, V., Thompson, E. R., Morley, T., MacRaild, S., et al. (2022) · Blood · doi:10.1182/blood.2022016090 · Cited by 116

Progress in targeting the BCL-2 family of proteins

Garner, T. P., López, A., Reyna, D. E., Spitz, A. Z., & Gavathiotis, E. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.014 · Cited by 109

Comparing the effects of different cell death programs in tumor progression and immunotherapy

Messmer, M. N., Snyder, A. G., & Oberst, A. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0214-4 · Cited by 109

Understanding MCL1: from cellular function and regulation to pharmacological inhibition

Sancho, M., Leiva, D., Lucendo, E., & Orzáez, M. (2021) · FEBS Journal · doi:10.1111/febs.16136 · Cited by 104

From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)

Papatzimas, J. W., Gorobets, E., Maity, R., Muniyat, M. I., MacCallum, J. L., Neri, P., Bahlis, N. J., & Derksen, D. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00455 · Cited by 103

Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer

Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1872 · Cited by 102

Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy

Yamaguchi, R., Lartigue, L., & Perkins, G. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.009 · Cited by 102

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma

Bajpai, R., Sharma, A., Achreja, A., Edgar, C. L., Wei, C., Siddiqa, A., Gupta, V. A., Matulis, S. M., McBrayer, S. K., Mittal, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15051-z · Cited by 103

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition

Roca-Portoles, A., Blanco, G. R., Sumpton, D. P., Cloix, C., Mullin, M., Mackay, G., O’Neill, K. L., Lemgruber, L., Luo, X., & Tait, S. W. G. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02867-2 · Cited by 103

BH3-mimetics: recent developments in cancer therapy

Townsend, P. A., Kozhevnikova, M. V., Cexus, O., Zamyatnin, A. A., & Soond, S. M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02157-5 · Cited by 109

Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy

Senichkin, V. V., Streletskaia, A. Y., Zhivotovsky, B., & Kopeina, G. S. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.03.004 · Cited by 103

Genetic characterization of ABT-199 sensitivity in human AML

Bisaillon, R., Moison, C., Thiollier, C., Krošl, J., Bordeleau, M.-È., Lehnertz, B., Lavallée, V., MacRae, T., Mayotte, N., Labelle, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0485-x · Cited by 105

Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition

Dey, J., Deckwerth, T. L., Kerwin, W. S., Casalini, J. R., Merrell, A., Grenley, M. O., Burns, C., Ditzler, S. H., Dixon, C., Beirne, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-18368-w · Cited by 99

Targeting BAX to drug death directly

Walensky, L. D. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0306-6 · Cited by 95

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS -Mutant Non–Small Cell Lung Cancer

Nangia, V., Siddiqui, F. M., Caenepeel, S., Timonina, D., Bilton, S. J., Phan, N., Gomez-Caraballo, M., Archibald, H. L., Li, C., Fraser, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0277 · Cited by 94

Life and Death of Activated T Cells: How Are They Different from Naïve T Cells?

Zhan, Y., Carrington, E. M., Zhang, Y., Heinzel, S., & Lew, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01809 · Cited by 100

OTUD1 Activates Caspase‐Independent and Caspase‐Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation

Luo, Q., Wu, X., Zhao, P., Nan, Y., Chang, W., Zhu, X., Su, D., & Liu, Z. (2021) · Advanced Science · doi:10.1002/advs.202002874 · Cited by 95

BH3-dependent and independent activation of BAX and BAK in mitochondrial apoptosis

Jeng, P., Inoue‐Yamauchi, A., Hsieh, J. J.-D., & Cheng, E. H. Y. (2018) · Current Opinion in Physiology · doi:10.1016/j.cophys.2018.03.005 · Cited by 100

Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation

Saller, B. S., Wöhrle, S., Fischer, L., Dufossez, C., Ingerl, I. L., Kessler, S., Tortola, M. M., Gorka, O., Lange, F., Cheng, Y., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.10.012 · Cited by 97

MCL-1 Inhibition by Selective BH3 Mimetics Disrupts Mitochondrial Dynamics Causing Loss of Viability and Functionality of Human Cardiomyocytes

Rasmussen, M. L., Taneja, N., Neininger, A. C., Wang, L., Robertson, G. L., Riffle, S., Shi, L., Knollmann, B. C., Burnette, D. T., & Gama, V. (2019) · iScience · doi:10.1016/j.isci.2020.101015 · Cited by 92

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Thijssen, R., Tian, L., Anderson, M. A., Flensburg, C., Jarratt, A., Garnham, A. L., Jabbari, J. S., Peng, H., Lew, T. E., Teh, C. E., et al. (2022) · Blood · doi:10.1182/blood.2022016040 · Cited by 94

Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition

Weeden, C. E., Ah-Cann, C., Holik, A. Z., Pasquet, J., Garnier, J.-M., Mérino, D., Lessène, G., & Asselin-Labat, M.-L. (2018) · Oncogene · doi:10.1038/s41388-018-0268-2 · Cited by 90

Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use

Brennan, M. S., Chang, C. W. T., Dewson, G., Tai, L., Lessène, G., Strasser, A., Kelly, G. L., & Herold, M. J. (2018) · Blood · doi:10.1182/blood-2018-06-859405 · Cited by 90

Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

Sun, X., Zhao, P., Lin, J., Chen, K., & Shen, J. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.16 · Cited by 90

Hot-Spots of Mcl-1 Protein

Denis, C., Santos, J. S. O., Bureau, R., & Voisin‐Chiret, A. S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00983 · Cited by 92

MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer

Wu, X., Luo, Q., Zhao, P., Chang, W., Wang, Y., Shu, T., Ding, F., Li, B., & Liu, Z. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814742116 · Cited by 89

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting

Slomp, A., Moesbergen, L. M., Gong, J., Cuenca, M., Borne, P. A. V. D., Sonneveld, P., Huang, D. C. S., Minnema, M. C., & Peperzak, V. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000702 · Cited by 88

Ancient and conserved functional interplay between Bcl-2 family proteins in the mitochondrial pathway of apoptosis

Popgeorgiev, N., Sa, J. D., Jabbour, L., Banjara, S., Nguyen, T. T. M., Akhavan-E-Sabet, A., Gadet, R., Ralchev, N., Manon, S., Hinds, M. G., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc4149 · Cited by 88

Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options

Wu, X., Luo, Q., & Liu, Z. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02760-y · Cited by 91

Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies – from pathogenesis to treatment

Vogler, M., Walter, H. S., & Dyer, M. J. S. (2017) · British Journal of Haematology · doi:10.1111/bjh.14684 · Cited by 89

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia

Wei, Y., Cao, Y., Sun, R., Cheng, L., Xiong, X., Jin, X. K., He, X., Lu, W., & Zhao, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584974 · Cited by 87

Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy

Kawiak, A., & Kostecka, A. (2022) · Cancers · doi:10.3390/cancers14020279 · Cited by 93

Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Glytsou, C., Chen, X., Zacharioudakis, E., Al-Santli, W., Zhou, H., Nadorp, B., Lee, S., Lasry, A., Sun, Z., Papaioannou, D., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0601 · Cited by 91

Too many targets, not enough patients: rethinking neuroblastoma clinical trials

Fletcher, J. I., Ziegler, D. S., Trahair, T. N., Marshall, G. M., Haber, M., & Norris, M. D. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0003-x · Cited by 86

Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer

Lin, K., Rutter, J. C., Xie, A., Pardieu, B., Winn, E. T., Bello, R. D., Forget, A., Itzykson, R., Ahn, Y.-R., Dai, Z., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0590-9 · Cited by 88

Targeting apoptosis in acute myeloid leukaemia

Cassier, P. A., Castets, M., Belhabri, A., & Vey, N. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.281 · Cited by 86

Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox

Lim, B., Greer, Y. E., Lipkowitz, S., & Takebe, N. (2019) · Cancers · doi:10.3390/cancers11081087 · Cited by 83

MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer

Dammert, M. A., Brägelmann, J., Olsen, R. R., Böhm, S., Monhasery, N., Whitney, C. P., Chalishazar, M. D., Tumbrink, H. L., Guthrie, M. R., Klein, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11371-x · Cited by 82

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Gupta, V. A., Barwick, B. G., Matulis, S. M., Shirasaki, R., Jaye, D. L., Keats, J. J., Oberlton, B., Joseph, N. S., Hofmeister, C. C., Heffner, L. T., et al. (2021) · Blood · doi:10.1182/blood.2020007899 · Cited by 82

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma

Průková, D., Anděra, L., Nahácka, Z., Karolová, J., Svatoň, M., Klánová, M., Havránek, O., Soukup, J., Svobodová, K., Zemanová, Z., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3275 · Cited by 81

IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis

Low, M. S. Y., Brodie, E. J., Fedele, P. L., Liao, Y., Grigoriadis, G., Strasser, A., Kallies, A., Willis, S. N., Tellier, J., Shi, W., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.097 · Cited by 87

MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib

Young, A. I. J., Law, A. M. K., Castillo, L. E., Chong, S., Cullen, H., Koehler, M., Herzog, S., Brummer, T., Lee, E. F., Fairlie, W. D., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0781-6 · Cited by 81

Iterative optimization yields Mcl-1–targeting stapled peptides with selective cytotoxicity to Mcl-1–dependent cancer cells

Araghi, R. R., Bird, G. H., Ryan, J. A., Jenson, J. M., Godes, M., Pritz, J. R., Grant, R. A., Letai, A. G., Walensky, L. D., & Keating, A. E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712952115 · Cited by 83

Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma

Slomp, A., & Peperzak, V. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00533 · Cited by 80

Targeting cholangiocarcinoma

Mertens, J. C., Ilyas, S. I., & Gores, G. J. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.027 · Cited by 80

Targeting MCL-1 protein to treat cancer: opportunities and challenges

Tantawy, S. I., Timofeeva, N., Sarkar, A., & Gandhi, V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1226289 · Cited by 90

Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia

Nwosu, G. O., Ross, D. M., Powell, J. A., & Pitson, S. M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06810-7 · Cited by 80

Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer

Guikema, J. E. J., Amiot, M., & Eldering, E. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1349754 · Cited by 83

Bacterial outer membrane vesicles and host cell death signaling

Dhital, S., Deo, P., Stuart, I., & Naderer, T. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.04.003 · Cited by 81

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients

Yuda, J., Will, C., Phillips, D. C., Abraham, L., Alvey, C. M., Avigdor, A., Buck, W. R., Besenhofer, L. M., Boghaert, E. R., Cheng, D., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00380-z · Cited by 79

Autophagy induced during apoptosis degrades mitochondria and inhibits type I interferon secretion

Lindqvist, L., Frank, D. O., McArthur, K., Dite, T. A., Lazarou, M., Oakhill, J. S., Kile, B. T., & Vaux, D. L. (2017) · Cell Death and Differentiation · doi:10.1038/s41418-017-0017-z · Cited by 82

Peptidomimetics: A Synthetic Tool for Inhibiting Protein–Protein Interactions in Cancer

Mabonga, L., & Kappo, A. P. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09831-5 · Cited by 81

Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity

Szlávik, Z., Ondi, L., Csékei, M., Paczal, A., Szabó, Z. B., Radics, G., Murray, J. B., Davidson, J. E. P., Chen, I., Davis, B. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00134 · Cited by 78

A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

Phillips, D. C., Jin, S. S., Gregory, G. P., Zhang, Q., Xue, J., Zhao, X., Chen, J., Tong, Y., Zhang, H., Smith, M. L., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0652-0 · Cited by 78

Killing SCLC: insights into how to target a shapeshifting tumorPreprint

Sutherland, K. D., Ireland, A. S., & Oliver, T. G. (2022) · Genes & Development · doi:10.1101/gad.349359.122 · Cited by 78

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Gomez‐Bougie, P., Maïga, S., Tessoulin, B., Bourcier, J., Bonnet, A., Rodríguez, M. S., Gouill, S. L., Touzeau, C., Moreau, P., Pellat‐Deceunynck, C., et al. (2018) · Blood · doi:10.1182/blood-2018-03-836718 · Cited by 81

Drug Resistance in Non-Hodgkin Lymphomas

Klener, P., & Klánová, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062081 · Cited by 78

Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1

Murray, J. B., Davidson, J. E. P., Chen, I., Davis, B. J., Dokurno, P., Graham, C. J., Harris, R., Jordan, A. M., Matassova, N., Pedder, C., et al. (2019) · ACS Omega · doi:10.1021/acsomega.9b00611 · Cited by 76

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells

Mukherjee, N., Skees, J., Todd, K. J., West, D. A., Lambert, K. A., Robinson, W. A., Amato, C. M., Couts, K. L., Gulick, R. J. V., MacBeth, M. L., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2646-2 · Cited by 76

Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death

Fresquet, V., Garcia-Barchino, M. J., Larráyoz, M., Celay, J., Vicente, C., Fernández‐Galilea, M., Larráyoz, M. J., Calasanz, M. J., Panizo, C., Junza, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1065 · Cited by 77

The third model of Bax/Bak activation: a Bcl-2 family feud finally resolved?

Luo, X., O’Neill, K. L., & Huang, K. (2020) · F1000Research · doi:10.12688/f1000research.25607.1 · Cited by 77

Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer

Lee, T., Christov, P. P., Shaw, S., Tarr, J. C., Zhao, B., Veerasamy, N., Jeon, K. O., Mills, J. J., Bian, Z., Sensintaffar, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01991 · Cited by 74

Mitochondrial metabolism as a target for acute myeloid leukemia treatment

Panina, S., Pei, J., & Kirienko, N. V. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00253-w · Cited by 74

JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1

Wu, X., Luo, Q., Zhao, P., Chang, W., Wang, Y., Shu, T., Ding, F., Li, B., & Liu, Z. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0339-0 · Cited by 76

BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL

Greaves, G., Milani, M., Butterworth, M., Carter, R. J., Byrne, D. P., Eyers, P. A., Luo, X., Cohen, G. M., & Varadarajan, S. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0183-7 · Cited by 73

Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics

Montero, J., & Haq, R. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1334 · Cited by 75

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Sale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12409-w · Cited by 75

Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers

Louault, K., Bonneaud, T. L., Séveno, C., Gomez‐Bougie, P., Nguyen, F., Gautier, F., Bourgeois, N., Loussouarn, D., Kerdraon, O., Barillé‐Nion, S., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0635-z · Cited by 72

From Biology to Therapy: The CLL Success Story

Yosifov, D. Y., Wolf, C. H., Stilgenbauer, S., & Mertens, D. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000175 · Cited by 76

BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics

Villalobos-Ortiz, M., Ryan, J. A., Mashaka, T., Opferman, J. T., & Letai, A. G. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0391-9 · Cited by 72

Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer

Ngoi, N. Y. L., Choong, C. S. H., Lee, J., Bellot, G. L., Wong, A. L. A., Goh, B. C., & Pervaiz, S. (2020) · Cancers · doi:10.3390/cancers12030574 · Cited by 73

Mcl-1 inhibition overcomes intrinsic and acquired Regorafenib resistance in Colorectal Cancer

Song, X., Shen, L., Tong, J., Kuang, C., Zeng, S., Schoen, R. E., Yu, J., Pei, H., & Zhang, L. (2020) · Theranostics · doi:10.7150/thno.45363 · Cited by 72

BCL-2: Long and winding path from discovery to therapeutic target

Schenk, R. L., Strasser, A., & Dewson, G. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.100 · Cited by 74

Selective targeting of antiapoptotic BCL‐2 proteins in cancer

Timuçin, A. C., Başağa, H., & Kütük, Ö. (2018) · Medicinal Research Reviews · doi:10.1002/med.21516 · Cited by 73

Demethylzeylasteral inhibits cell proliferation and induces apoptosis through suppressing MCL1 in melanoma cells

Zhao, Y., He, J., Li, J., Peng, X., Wang, X., Dong, Z., Zhao, E., Liu, Y., Wu, Z., & Cui, H. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.529 · Cited by 71

Inhibition of cancer stem cell like cells by a synthetic retinoid

Chen, J., Cao, X., An, Q., Zhang, Y., Li, K., Yao, W., Shi, F., Pan, Y., Jia, Q., Zhou, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03877-7 · Cited by 71

Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis

Arai, S., Jonas, O. H., Whitman, M. A., Corey, E., Balk, S. P., & Chen, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0549 · Cited by 72

A Non-apoptotic Function of MCL-1 in Promoting Pluripotency and Modulating Mitochondrial Dynamics in Stem Cells

Rasmussen, M. L., Kline, L. A., Park, K. P., Ortolano, N. A., Romero-Morales, A. I., Anthony, C. C., Beckermann, K. E., & Gama, V. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.005 · Cited by 72

Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma

Manzano, M., Patil, A., Waldrop, A., Davé, S. S., Behdad, A., & Gottwein, E. (2018) · Nature Communications · doi:10.1038/s41467-018-05506-9 · Cited by 72

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer

Annunziato, S., de Ruiter, J. R., Henneman, L., Brambillasca, C. S., Lutz, C., Vaillant, F., Ferrante, F., Drenth, A. P., van der Burg, E., Siteur, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08301-2 · Cited by 69

Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment

Schenk, R. L., Tuzlak, S., Carrington, E. M., Zhan, Y., Heinzel, S., Teh, C. E., Gray, D. H. D., Tai, L., Lew, A. M., Villunger, A., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2016.156 · Cited by 68

Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies

Montero, J., Gstalder, C., Kim, D. J., Sadowicz, D. E., Miles, W. O., Manos, M. P., Cidado, J. R., Secrist, J. P., Tron, A. E., Flaherty, K. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12477-y · Cited by 71

Cell death pathologies: targeting death pathways and the immune system for cancer therapy

Pentimalli, F., Grelli, S., Daniele, N. D., Melino, G., & Amelio, I. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0052-x · Cited by 69

MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation

Arai, S., Varkaris, A. S., Nouri, M., Chen, S., Xie, L., & Balk, S. P. (2020) · eLife · doi:10.7554/elife.54954 · Cited by 71

It's time to die: BH3 mimetics in solid tumors

Kehr, S., & Vogler, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118987 · Cited by 67

Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors

Johannes, J. W., Bates, S. M., Beigie, C., Belmonte, M. A., Breen, J. N., Cao, S., Centrella, P. A., Clark, M., Cuozzo, J. W., Dumelin, C. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00464 · Cited by 67

Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design

Shaw, S., Bian, Z., Zhao, B., Tarr, J. C., Veerasamy, N., Jeon, K. O., Belmar, J., Arnold, A. L., Fogarty, S. A., Perry, E., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01155 · Cited by 67

FBW7 -Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors

Tong, J., Tan, S., Nikolovska‐Coleska, Z., Yu, J., Zou, F., & Zhang, L. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0032 · Cited by 66

MCL1 Can Be Targeted to Induce Apoptosis in Multiple Cancer Types

(2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2016-207

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

Maragno, A. L., Mistry, P., Kotschy, A., Szlavik, Z., Murray, J., Davidson, J. E. P., Toumelin-Braizat, G. L., Chanrion, M., Bruno, A., Clapéron, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4482 · Cited by 15

Development and Characterization of Novel Mcl-1 Inhibitors for Treatment of Cancer.

Mady, A. S. A. (2016) · Deep Blue (University of Michigan) · Cited by 1

Targeting MCL-1 in cancer: current status and perspectives

Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 318

Targeting MCL‐1 to Overcome Therapeutic Resistance and Improve Cancer Mortality

Mohiuddin, M. (2025) · Health Science Reports · doi:10.1002/hsr2.71390 · Cited by 9